Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%

Low Eosinophil Patients Have 39% Reduction, Supporting Broad Label

 
• By Mandy Jackson
Shortness of breath
Tezepelumab cut asthma exacerbations on top of standard-of-care drugs • Source: Shutterstock

More from Respiratory

More from Therapeutic Category